FLNC and familial dilated cardiomyopathy: A combined analysis of truncating and nontruncating variants showed that in DCM patients, aggregated protein-altering variants in TTN (case, 31.7%, 66/208 vs. reference, 14.8%, 84/568), filamin C (FLNC) (case, 15.4%, 32/208 vs. reference, 2.1%, 12/568), and LMNA (case, 4.3%, 9/208 vs. reference, 0.5%, 3/568) were significantly enriched (Fig. 3A, Table 2).